NCT00280176View on ClinicalTrials.gov

Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

November 30, 2008

Study Completion Date

September 30, 2010

Conditions
Colorectal Cancer
Interventions
DRUG

bortezomib

0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks

DRUG

fluorouracil

225mg/m2 given weekly, up to 6 weeks

RADIATION

radiation therapy

180 cGy, every 5 days, up to six weeks

Trial Locations (2)

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT00280176 - Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer | Biotech Hunter | Biotech Hunter